Clinical efficacy
Tumor, soft-tissue sarcomas
TUMOR
In the intention-to-treat population, 6 of 19 patients achieved confirmed partial responses with MASCT-I plus camrelizumab and apatinib, resulting an ORR of 31.6% (95% CI, 12.6–56.6). The DCR was 68.4% (95% CI, 43.5–87.4). In total, 13 of 19 (68.4%) patients showed a decrease from baseline in the size of target lesions (Fig. Tumor response. Kaplan–Meier estimates of progression-free survival. Patients in the schedule-II group showed similar ORR with those in the schedule-I group (30.0% versus 33.3%) but had higher DCR (90.0% versus 44.4%; Table Tumor responsesData are Among the 13 patients with soft-tissue sarcomas, 4 achieved confirmed partial responses (Table 